There was also a tendency toward a higher Th17 to Tregs ratio, based on CD4+IL-17+/CD4+Foxp3+ (p=0.055), differentiating advanced MASLD patients from those with early MASLD, and providing insight into the balance between pro-inflammatory and immune-suppressing responses (Figure 2B). The gene discussed is CD4; the disease is metabolic dysfunction-associated steatotic liver disease.